Lifting the veil on the 340B drug pricing program: Overview and recent developments
BY Michael R. Alexander, Esq. and Kianna Sitarski, Esq., Brown & Fortunato, P.C. As healthcare costs across the United States continue to rise, healthcare providers are feeling the financial squeeze associated with increasing costs of providing necessary products and services coupled with the trend of decreasing reimbursement rates paid out from patient healthcare plans. One method by which providers and healthcare systems may ease this financial burden is through participation in the 340B Drug...